Biotech

Interest in the field of health economics and outcomes research (HEOR) has grown exponentially as governments and other payers grapple with how to provide the best possible health outcomes at affordable costs. Renowned as the global Society that convenes all healthcare stakeholders in HEOR, ISPOR is leading the field at a time when solid approaches to decision making are more important than ever.

The European Medicines Agency (EMA) have issued a network strategy to 2025 with the mission: Protecting Public Health at a Time of Rapid Change. The strategic focus areas are availability and accessibility of medicines, data analytics-digital tools and digital transformation, innovation, anti-microbial resistance, other emerging health threats, supply chain challenges, sustainability of the network and operational excellence. This sets the framework for the 2022 ISPE Europe Annual Conference in Madrid in April. High level speakers from the European Commission, the European Federation of Pharmaceutical Industries’ Associations (EFPIA) as well as European National Competent Authorities engaged in sustainability will give input to ISPEs well known traditional Executive Forum. Special focus will feature industry speakers on learnings from the COVID-19 crisis and the management of vaccine production and logistics.

Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs – join the discussion in Dublin, or attend from home via a digital pass. Plus take advantage of two bonus days of digital 1×1 meetings. Additional details to be released shortly, check back for updates.

[From 2021] The BIO Investor Forum Digital is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and BIO One-on-One Partnering™ meetings.

Bio Connections Australia explores drug development, early phase clinical trials, translational research and expediting Australia’s great science into commercialization.

For more than 20 years, the BIO CEO & Investor Conference has fueled the biotech industry networking with premier investor and banking communities, focused on established and emerging publicly traded and select private biotech companies. 

The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies, where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

Join thousands of international thought leaders to discuss the latest research, technologies, innovation and business models in implementing precision medicine, biomarkers and companion diagnostics, genomic medicine, and precision health; innovation and market access strategies for at-home diagnostics, point-of-care testing and molecular diagnostics for infectious diseases; liquid biopsy and advanced diagnostics for precision oncology, including Multi-Cancer Early Detection and Minimal Residual Disease testing; and emerging technologies for spatial biology and single-cell multiomics.

The Association of American Cancer Institutes (AACI) Clinical Research Innovation (CRI) program serves as a network for research leaders to develop and share best practices for the efficient operation of clinical trials offices (CTO) at AACI cancer centers. The programming of the 14th Annual AACI CRI Meeting, “Partnering in Progress,” aligns with CRI’s strategic goal of stimulating cancer center interactions to maximize resources by creating opportunities for peer-to-peer networking and collaboration.